Posts Tagged ‘biopharmaceuticals’

Chelsea Therapeutics (CHTP) stocks soar on new drug application

Monday, April 18th, 2011

Chelsea Therapeutics International Ltd. (Nasdaq: CHTP) shares rose 24.4% Monday after the biotechnology company said it would file a new application for its hypotension treatment in the third quarter. The Charlotte-based company traded in 3.1 million shares, which sold for $4.95, or 97 cents better than Friday’s close.

The Company reaffirmed its NORTHERA™ (droxidopa) new drug application (NDA) filing strategy following correspondence with the U.S. Food and Drug Administration (FDA) regarding recent data from Northera Study 306A and protocol amendments to ongoing Northera Study 306B, comparing the rate of patient reported falls associated with symptomatic neurogenic orthostatic hypotension (NOH) in patients with Parkinson’s disease (PD) taking Northera versus placebo.

According to Chelsea President and CEO Dr. Simon Pedder, “We believe the remarkable safety and tolerability of Northera coupled with the robust clinical benefit demonstrated throughout our Phase III program provide a strong basis for the approval of Northera as a novel treatment for symptomatic neurogenic orthostatic hypotension.”

Pedder continued, “We continue to be appreciative of the guidance that the FDA has provided to Chelsea as we prepare to file this new NDA in the third quarter of 2011. Following the approval of Northera, we look forward to building on the clinical work currently underway in Study 306B and completing the necessary studies to allow for a post-marketing expansion of the label including a claim that Northera reduces falls in neurogenic orthostatic hypotension from Parkinson’s Disease.”

Chelsea is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases.

LZR merges, MSFT moving, CRME skips a beat

Monday, February 7th, 2011

Emergent Group Inc. (AMEX: LZR) shares sprang up 38.8 per cent to $8.41, on volume of 284,325 or more than 11 times its daily average. Monday, it was announced that LZR was to be acquired by Universal Hospital Services for $8.46 a share.

Microsoft Inc. (Nasdaq: MSFT) traded in 25.3 million shares, pursuing a daily average of 58.4 million. Share prices added 1.6 percent to $28.22, amid general momentum in the tech world.

Cardiome Pharma Corporation (Nasdaq: CRME) lost 11.4 percent Monday to $6.06. Volume was 561,971 shares, nearly twice its normal daily average. Vancouver-based CRME is a product-focused drug development company dedicated to the advancement and commercialization of novel treatments for disorders of the heart and circulatory system.

ACAT prowls, MSFT big trader, MRNA sinks

Thursday, January 27th, 2011

Arctic Cat Inc. (Nasdaq: ACAT) shares improved 15.3 percent Thursday to $15.82. Volume was 224,068 shares, better than double its daily average, on quarterly revenues of $152 million, beating estimates of $136.8 million.

Microsoft Corporation (Nasdaq: MSFT) traded in 22.7 million shares Thursday, building toward a daily average of 58.3 million. Share prices stepped down 0.6 percent to $28.61

Marina Biotech Inc. (Nasdaq: MRNA) shares let go of 9.1 percent to $1.09 Thursday, on volume of 580,004 shares, beating its daily average of 234,217, on Japanese patent news concerning one of its nucleic acid products.

ZBB zips along, PFE has healthy volume, ICGN downward

Thursday, January 20th, 2011

ZBB Energy Corporation (AMEX: ZBB) gained 14.8 percent Thursday to $1.24, on volume of 1,384,173 shares, more than four times its full-day average, after signing lucrative contracts in China.

Pfizer Inc. (NYSE: PFE) dealt in 43,708,033 shares, to within a few aces of its full-day average of 45,414,700. Share prices were flat at $18.27

Icagen Inc. (Nasdaq: ICGN) dipped 17 percent to $2.44. Volume was 1,761,812 shares, four times its daily average.

THLD breaks down door, INTC active, DRWI scorched

Thursday, January 13th, 2011

Threshold Pharmaceuticals Inc. (Nasdaq: THLD) shares gained 16.9 percent to $2.01 Thursday. Volume was 606,335, triple its full-day volume average. THLD is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors.

Intel Corporation (Nasdaq: INTC) traded in 47,608,915 shares Thursday, catching up to its daily average of 55,807,500. Prices for the chip maker were off 0.3 percent to $21.24.

DragonWave Inc. (Nasdaq: DRWI) fell 15.4 percent Thursday to $7.33 Volume for the stock was 3,399,796 shares proved nearly seven times its full-day average. Wednesday, the Ottawa-based DRWI announced quarterly figures showing revenue of $27.0 million, compared with $51.6 million in the third quarter of fiscal year 2010. Net loss in the third quarter of fiscal year 2011 was $0.05 million, compared to net income of $11.6 million in the prior-year quarter.